Page last updated: 2024-10-26

ethosuximide and Down Syndrome

ethosuximide has been researched along with Down Syndrome in 3 studies

Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.

Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)

Research Excerpts

ExcerptRelevanceReference
"Agranulocytosis caused by ethosuximide is extremely rare in children."7.72Ethosuximide induced agranulocytosis. ( Imai, T; Itoh, S; Kawada, K; Kusaka, T; Nanba, M; Okada, H, 2003)
" As a corollary, they also show that long-term use of ETH and GAB is devoid of adverse behavioral and cognitive effects."5.38Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Flórez, J; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sharma, A; Vidal, V, 2012)
"Agranulocytosis caused by ethosuximide is extremely rare in children."3.72Ethosuximide induced agranulocytosis. ( Imai, T; Itoh, S; Kawada, K; Kusaka, T; Nanba, M; Okada, H, 2003)
" As a corollary, they also show that long-term use of ETH and GAB is devoid of adverse behavioral and cognitive effects."1.38Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Flórez, J; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sharma, A; Vidal, V, 2012)
"Children with Down syndrome are highly susceptible to infantile spasms."1.35Infantile spasms and Down syndrome: a new animal model. ( Aleem, IS; Ashraf, A; Cortez, MA; Kanawaty, A; Liu, CC; Sadeghnia, HR; Shen, L; Snead, OC; Stewart, L; Trepanier, CH; Wu, Y, 2009)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cortez, MA1
Shen, L1
Wu, Y1
Aleem, IS1
Trepanier, CH1
Sadeghnia, HR1
Ashraf, A1
Kanawaty, A1
Liu, CC1
Stewart, L1
Snead, OC1
Vidal, V1
García, S1
Martínez, P1
Corrales, A1
Flórez, J1
Rueda, N1
Sharma, A1
Martínez-Cué, C1
Imai, T1
Okada, H1
Nanba, M1
Kawada, K1
Kusaka, T1
Itoh, S1

Other Studies

3 other studies available for ethosuximide and Down Syndrome

ArticleYear
Infantile spasms and Down syndrome: a new animal model.
    Pediatric research, 2009, Volume: 65, Issue:5

    Topics: 4-Butyrolactone; Animals; Anticonvulsants; Baclofen; Brain; Disease Models, Animal; Down Syndrome; E

2009
Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome.
    Neuroscience, 2012, Sep-18, Volume: 220

    Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cognition; Cyclohexanecarboxylic Acids; Disease

2012
Ethosuximide induced agranulocytosis.
    Brain & development, 2003, Volume: 25, Issue:7

    Topics: Agranulocytosis; Anticonvulsants; Down Syndrome; Ethosuximide; Fever; Humans; Infant; Male

2003